Galapagos Genomics NV Appoints David Smith As Chief Financial Officer

Mechelen, Belgium, Nov. 9, 2005 (PRIMEZONE) -- Galapagos (Euronext:GLPG) (LSE:GLPG), a genomics-based drug discovery company, has appointed David R. Smith as Chief Financial Officer to Galapagos per February 1, 2006. With this appointment, Galapagos further strengthens its Executive Committee to lead the Company in its next phase of development. David Smith joins Galapagos from AstraZeneca Netherlands. Upon his arrival, Vicky Gwosdz, currently Head of Finance of Galapagos, will continue as Controller at Galapagos.